英国制药巨头阿斯特捷利康(AstraZeneca)周五宣布,将投资25亿美元在北京建立研发中心。
根据协议,阿斯特捷利康将与生技公司和铂医药(02142.HK) 和Syneron Bio进行研发合作,并与BioKangtai成立合资企业,开发、生产和销售呼吸道和其他传染病疫苗。(me/t)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.